Market Research Blog – Page 2 – Just another WordPress site

Global Chronic Obstructive Pulmonary Disease Industry Poised for Steady Growth at 4.4% CAGR, Reaching US$33.2 Billion by 2033 | FMI

The Global Chronic Obstructive Pulmonary Disease Industry is on track for consistent growth, driven by a rising disease burden. According to Future Market Insights (FMI), the market reached an estimated value of US$21.58 billion in 2023. Looking ahead, it’s projected to climb to US$33.19 billion by 2033, reflecting a Compound Annual Growth Rate (CAGR) of 4.4%.

The study’s conclusions highlight the crucial influence of changing lifestyle choices, with alcohol use appearing as a major factor in the rising cost of treatments for chronic obstructive pulmonary disease (COPD). According to the study, the growing incidence of COPD, which is made worse by rising alcohol consumption, is a primary driver behind the anticipated market expansion over the next decade.

Request a Sample PDF Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16215

Additionally, the World Health Organization (WHO) states that the most common cause of COPD is exposure to tobacco smoke both via first-hand as well as second-hand smoking. This global increase in the prevalence of COPD is a major factor fueling the growth of the COPD market in the forthcoming years. In addition, the rise in consumption of tobacco among millennials, coupled with the rise in the awareness among the population, regarding the use of generic drugs are projected to contribute to the revenue share of the chronic obstructive pulmonary disease market shortly.

According to the Centers for Disease Control and Prevention (CDCP), the cost related to COPD in the US was 32.1 $ billion in 2010 and rose to 49 billion by 2020. Hence, the continual growth witnessed in the cases of COPD among the population worldwide is a major factor that will intensify the growth of the COPD market over the forecast period.

Key Takeaways from the Global Chronic Obstructive Pulmonary Disease Industry Study

The global Chronic Obstructive Pulmonary Disease (COPD) Market was valued at US$ 20.67 Billion by 2022-end
From 2018 to 2022, the market demand expanded at a CAGR of 2.4%
By Type, the Chronic Bronchitis segment of the market constitutes the bulk of the market with a market share of 43%
By Distribution Channel, the Retail Pharmacies segment dominates the market with a share of 42%
From 2023 to 2033, Chronic Obstructive Pulmonary Disease (COPD) sales are expected to flourish at a CAGR of 4.4%.
By 2033, the market value of Chronic Obstructive Pulmonary Disease (COPD) is expected to reach US$ 33.19 Billion.

Contact us for Discount
https://www.futuremarketinsights.com/request-discount/rep-gb-16215

The continual increase in cases of COPD globally, coupled with rising cases of tobacco consumers are the major factors escalating the growth of the Chronic Obstructive Pulmonary Disease (COPD) market shortly, remarks an FMI analyst.

Global Chronic Obstructive Pulmonary Disease Industry Competitive Landscape

Prominent players in the Chronic Obstructive Pulmonary Disease (COPD) market are Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Kyowa Hakko Kirin, Mylan N.V., Novartis AG, Orion Corporation, Sanofi, Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.), Teva Pharmaceutical Industries Ltd., Theravance Biopharma, and Verona Pharmaceuticals, among others.

Recent Developments In the Global Chronic Obstructive Pulmonary Disease Industry:

In June 2022, Verona Pharma, a pharmaceutical company, announced the completion of the patient enrolment, with more than 800 subjects involved in its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. It is a critical step for the phase III ENHANCE trial with top-line data expected by the end of the year 2022 and further data from ENHANCE-2 in the third quarter of 2022.
In May 2022, Alembic Pharmaceuticals Ltd, a pharmaceutical company, received final approval from the US health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the U.S. Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for the strength of 15 mcg (base)/2 mL unit-dose vial.

Know More About What the Global Chronic Obstructive Pulmonary Disease Industry Report Covers

Future Market Insights offers an unbiased analysis of the global Chronic Obstructive Pulmonary Disease (COPD) Market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033. To understand opportunities in the Chronic Obstructive Pulmonary Disease (COPD) Market, the market is segmented based on drug class, type, and distribution channel, across five major regions.

Visit for Customization
https://www.futuremarketinsights.com/customization-available/rep-gb-16215

Key Segments Covered in the Global Chronic Obstructive Pulmonary Disease Industry Analysis

Global Chronic Obstructive Pulmonary Disease Industry by Drug Class:

Combination Therapy
Bronchodilators
Corticosteroids
Phosphodiesterase Type 4 Inhibitor
Mucokinetics
Others

by Type:

Chronic Bronchitis
Emphysema

by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

by Region:

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Hermansky Pudlak Syndrome Therapeutics Market for Explosive Growth, Projected to Reach US$ 12 Billion by 2033 at a 7.2% CAGR

The global Hermansky-Pudlak Syndrome (HPS) therapeutics market was valued at US$ 6 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2033, when it is predicted to reach US$ 12 billion. The development of the global hermansky pudlak syndrome therapeutics market is mostly due to high costs associated with R&D activities related to the manufacture of recombinant factors and advancements in patient treatment technologies.

The industry is propelled by a sizable customer base that is becoming more conscious of pressing issues, accessible fixes, and advantageous recompense practices. The expiration of existing brands’ patents will make the profitable Hermansky Pudlak Syndrome Therapeutics market more accessible to generic medication makers.

Preview Next-Level Insights Sample:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16294

The market for hermansky pudlak syndrome therapeutics is primarily centered in Western countries like North America and Europe because branded drugs are very expensive. Low-cost drugs would help enter markets in developing and impoverished countries where patients cannot afford pricey medical treatments. Consequently, the Middle East and Africa, Asia-Pacific (APAC), and Latin America would see rapid market expansion due to the accessibility of affordable generic medications.

Market Competition

Leading hermansky pudlak syndrome Therapeutics companies are concentrating on strategic initiatives such as partnership development, acquisitions, mergers, and others. These steps are being taken to improve the market position.

Recent Developments:

In October 2022, Ferring Pharmaceuticals and Blackstone Life Sciences announced a restructured cooperation in nadofaragene firadonavec, an experimental new gene therapy in late-stage research for patients with high-grade, Bacillus Calmette-Guerin refractory, non-muscle invasive bladder cancer.
In August 2022, American Regent, Inc., a California-based maker of medicines for human and veterinary use with production facilities in New York and Ohio, announced the acquisition of HBT Labs, Inc. HBT Labs offers a pipeline of generic and 505(b)(2) pharmaceutical medicines that target a variety of therapeutic indications, including cancer and CNS diseases.

Key Companies Profiled:

American Regent
Dr. Reddy’s
Gland Pharma Limited
Sagent Pharma
Sun Pharma
Teva Pharmaceuticals
Ferring Pharmaceuticals
UbiPharm
Allergan PLC
Glenmark Pharmaceuticals

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16294

Key Segments Profiled in the Hermansky Pudlak Syndrome Therapeutics Industry Survey:

By Therapies:

Transfusions of Normal Blood Platelets
Oral Contraceptives
Desmopressin Acetate

By Application:

Hospitals
Clinics
Over the Counters

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)

Discover Detailed Market Analysis: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16294

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Human Immunodeficiency Virus Type 1 (HIV-1) Industry is predicted to develop at a consistent 6% CAGR to reach US$ 62 Billion By 2033 | FMI

The fight against HIV/AIDS is reaching a significant milestone, with the Global Human Immunodeficiency Virus Type 1 (HIV-1) Industry projected to reach a remarkable US$34.83 billion in 2023. This noteworthy valuation signifies a turning point in the battle against the disease.

Fueled by a compound annual growth rate (CAGR) of 6%, the market is expected to maintain a steady trajectory, reaching an estimated US$56.6 billion by 2033 according to a comprehensive analysis by the Institute for Health Metrics and Evaluation.

The industry’s consistent expansion may be mainly ascribed to the ongoing increase in the prevalence of HIV-1 infections worldwide. Despite advancements in treatment options, approximately 37 million people globally are affected by the rising number of new cases. It’s interesting to note that the death rate linked to HIV-1 has not changed significantly over time, highlighting the urgency of

Currently, only half of the affected population has access to antiretroviral therapeutic interventions for disease management. This underscores a substantial gap in treatment accessibility that the healthcare industry aims to address over the forecasted decade.

Request a Sample of this Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16202

Because of the large percentage of HIV patients in highly populous countries such as China and India, the Asia Pacific market is expected to become the fastest-growing market with the highest CAGR over the coming years. Furthermore, the massive amount of therapeutic interventions, as well as monetary support from corporate companies and medical companies, are anticipated to propel the industry forward.

Key Takeaways from the Global Human Immunodeficiency Virus Type 1 (HIV-1) Industry Study

North America led the 2022 market with a sales volume of US$ 21 Billion.
According to a study conducted by the Centers for Disease Control (CDC) in 2021, an estimated 1.2 million people had HIV at the end of 2018.
Based on the World Health Organization (WHO), approximately 33.0 million people will be infected with HIV by 2021.
Women and girls comprised 54% of all HIV-positive people, according to the WHO.
From 2018 to 2022, sales increased significantly at a CAGR of 1.6%.

Global Human Immunodeficiency Virus Type 1 (HIV-1) Industry Players

Key players in the Human Immunodeficiency Virus Type 1 (HIV 1) market are AbbVie, Inc., Boehringer, and Ingelheim GmbH. Bristol-Myers Squibb Company, Cipla, Inc., Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline, Sanofi.

In July 2021 – Unitaid and the Clinton Health Access Initiative, Inc. (CHAI) announced a pricing agreement with the medical company Hetero Labs LTD to make darunavir plus ritonavir (DRV/r) available as a second-line treatment for HIV patients in low and middle-income countries for US$ 210 per patient/year.
In March 2021, Gilead Sciences Inc. and Merck announced a collaboration agreement to co-develop and co-commercialize long-term HIV treatment. The investigational capsid inhibitor lenacapavir from Gilead and the investigational nucleoside reverse transcriptase translocation inhibitor islatravir from Merck will be paired to form a two-drug HIV regimen.
On January 20, 2021 – HIV ViiV Healthcare evolved Cabenuva, an injectable drug approved by the US Food and Drug Administration for the treatment of human immunodeficiency virus type 1 (HIV) infections in adults.

Request for Customization:
https://www.futuremarketinsights.com/customization-available/rep-gb-16202

Key Segments Profiled in the Global Human Immunodeficiency Virus Type 1 (HIV-1) Industry Survey

Global Human Immunodeficiency Virus Type 1 (HIV-1) Industry by Drug Class:

Nucleoside-Analog Reverse Transcriptase Inhibitor
Non-Nucleoside Reverse Transcriptase Inhibitor
Entry and Fusion Inhibitors
Protease Inhibitors
Integrase Inhibitors
Coreceptor Antagonists

Global Human Immunodeficiency Virus Type 1 (HIV-1) Industry by Region:

North America
Europe
Asia Pacific
Latin America
Middle East and Africa (MEA)

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Nandini Singh Sawlani

Global Multiple System Atrophy (MSA) Therapeutics Market Continues Upward Trajectory, Projected to Reach US$ 211.1 Million by 2033 at a 4.4% CAGR

The global Multiple System Atrophy (MSA) therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 4.4%, with a current valuation of US$ 137.3 million by 2023. Healthcare technology advancements are expected to drive the market to US$ 211.1 million by 2033.

Multiple system atrophy (MSA) is a neurodegenerative disorder that causes symptoms that affect both the autonomic nervous system and movement. The multiple system atrophy causes are unknown, and most cases are sporadic. The accumulation of alpha-synuclein is a distinguishing feature of MSA.

Preview Next-Level Insights Sample :
https://www.futuremarketinsights.com/reports/sample/rep-gb-16285

Key Takeaways:

The MSA therapeutics market is expected to reach US$211.1 million by 2033, driven by a CAGR of 4.4%.
Limited treatment options for MSA highlight the significant need for novel therapies.
Technological advancements in gene therapy and other areas hold promise for the future of MSA treatment.
Growing disease awareness is leading to earlier diagnosis and a greater demand for effective treatments.

Competitive Landscape:

Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc., Merck & Co., Neuropore Therapies Inc, Newron Pharmaceuticals SpA, ProMIS Neurosciences Inc, Stealth BioTherapeutics Corp, Chelsea Therapeutics International, Ltd. are some of the key players in the multiple system atrophy therapeutics industry.

The manufacturers are involved in the production of multiple system atrophy therapeutics in a larger capacity. Research and innovation are also conducted to launch innovative products for multiple system atrophy therapeutics.

Also, some of the key players are acquiring small pharmaceutical companies to increase their production capacity. Suppliers are focusing on expanding their market presence across the world by initiating new product launches and boosting sales.

In April 2022, ProMIS Neurosciences, Inc. a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced new milestones in potential therapeutic approaches for ALS.
In October 2022, Biohaven Ltd. announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, and infectious and autoimmune diseases.

Explore Our Methodology Framework:
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16285

Key Companies Profiled:

Biohaven Pharmaceuticals, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
AstraZeneca plc
Theravance Biopharma, Inc.
Merck & Co.
Neuropore Therapies Inc
Newron Pharmaceuticals SpA
ProMIS Neurosciences Inc
Stealth BioTherapeutics Corp
Chelsea Therapeutics International, Ltd.

Key Segments Covered in the Multiple System Atrophy (MSA) Market Industry Survey:

Multiple System Atrophy (MSA) Therapeutics Market by Type:

Parkinsonian
Cerebellar

Multiple System Atrophy (MSA) Therapeutics Market by Diagnosis:

Magnetic Resonance Imaging (MRI)
Positron Emission Tomography (PET)
Single Photon Emission Computed Tomography (SPECT)
Tilt Table Test
Others

Multiple System Atrophy (MSA) Therapeutics Market by RegionP:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)

Obtain In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16285

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Pancreatic Cancer Industry Expected to Reach US$7.5 Billion by 2033, Driven by Steady Growth at 13.5% CAGR | FMI Analysis

The Global Pancreatic Cancer Industry is poised for significant growth, according to a groundbreaking new analysis from Future Market Insights Inc. (FMI), a leading healthcare research firm. The market is expected to reach a valuation of approximately US$2,125.57 million by the end of 2023. Looking ahead, the market is projected to climb at a robust Compound Annual Growth Rate (CAGR) of 13.5%, reaching an impressive US$7,541.09 million by 2033.

Among the most common types of cancer in the world, pancreatic cancer is a serious illness with far-reaching consequences. The fact that HPV is the seventh most common cause of cancer-related deaths worldwide, according to alarming data, emphasizes how urgent it is to address this pressing healthcare issue.

The analysis further highlights a notable upward trend in the prevalence of pancreatic cancer, particularly in the Western world. Of concern is the rise in cases of pancreatic adenocarcinoma within developed regions. Lifestyle factors, including alcohol consumption and obesity, are believed to be substantial contributors to this worrisome trend.

Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-16183

Why Choose Future Market Insights

Serving domestic and international clients 24/7
Prompt and efficient customer service
Data collected from reliable primary and secondary sources
Highly trained and experienced team of research analysts
Seamless delivery of tailor-made market research reports

Global Pancreatic Cancer Industry: Segmentation

Valuable information covered in FMI’s Global Pancreatic Cancer Industry report has been segregated into key segments and sub-segments.

By Treatment Type:

Chemotherapy
Immunotherapy
Hormone Therapy
Surgery
Radiation Therapy
Targeted Drug Therapy
Others

Grab Your Discount Now Before It’s Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-16183

By Cancer Type:

Endocrine Pancreatic Cancer
Exocrine Pancreatic Cancer

By End User:

Hospitals
Clinics
Diagnostic Laboratories
Research Institutes
Research Laboratories
Others

Global Pancreatic Cancer Industry: Competition Analysis

The FMI’s study presents a comprehensive analysis of global, regional, and country-level players active in the Global Pancreatic Cancer Industry. Competitive information detailed in the Pancreatic Cancer market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Global Pancreatic Cancer Industry report.

Key players covered in the Global Pancreatic Cancer Industry report include:

Pfizer Inc.
Novartis AG
Eli Lily and Company
Bristol Myers Squibb Company
Zydus Cadila
Myriad Genetics Inc.
F-Hoffmann-La Roche Ltd.
PharmaCyte Biotech Inc.
Teva Pharmaceutical Industries Ltd.

Get Your Customized Impactful Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-16183

Important Questions Answered in the Global Pancreatic Cancer Industry Report

Which end-user remains the top revenue contributor in different regional markets?
At what rate has the global Global Pancreatic Cancer Industry been expanding during the forecast period?
How will the global Pancreatic Cancer market look like by the end of the forecast period?
What innovative strategies are adopted by Global Pancreatic Cancer Industry players to stay ahead of the pack?
What are the restraints affecting the growth of the global Pancreatic Cancer market?

Key Offerings of the Report

Growth Drivers and Opportunities: Comprehensive analysis of growth-driving factors and opportunities for market players in different regional markets
Recent Trends and Forecasts: Detailed assessment of the latest trends, technological developments, and forecasts for a 5-year or 10-year period.
Segmental Analysis: Extensive analysis of each segment and factors differentiating the role of these segments in market revenue forecasts and growth rate analysis
Regional Market Forecast: Thorough analysis of each regional market to arm stakeholders with the necessary information to make critical decisions
Competitive Landscape: All-inclusive insights on both leading and emerging players vying for a slice of the Global Pancreatic Cancer Industry

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Nandini Singh Sawlani

Global Non-Small Cell Lung Carcinoma Industry Expected to Reach US$21.4 Billion by 2033, Driven by 10% CAGR Growth | FMI

The Global Non-Small Cell Lung Carcinoma Industry is on a trajectory for significant growth, fueled by a robust Compound Annual Growth Rate (CAGR) of 10% projected from 2023 to 2033. According to market analysts, the market is expected to reach an impressive US$8.25 billion by 2023, and a staggering US$21.40 billion by 2033. This growth highlights the increasing focus on the diagnosis and treatment of this prevalent form of lung cancer.

Carefully considered insights obtained by FMI, the leading authority on healthcare insights and data, serve as the foundation for this revolutionary change. Utilizing the most recent data obtained from significant global producers of pharmaceuticals and medical equipment, FMI offers a comprehensive study of the Non-Small Cell Lung Carcinoma (NSCLC) market, offering unmatched insight into the future of the sector.

Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-16180

Over the past decade, the healthcare sector has expanded remarkably, following the advent of artificial Intelligence and the Internet of Things integrated medical devices. Advancements in technology have created impressive scope within the medical sector for diagnostics and therapeutics.

The report offers extensive data sets validating key trends impacting growth in the Non-Small Cell Lung Carcinoma (NSCLC) Industry. It offers insights into strategies adopted by the key players and addresses the concerns that will challenge the growth of the Non-Small Cell Lung Carcinoma (NSCLC) Industry. With our extensive research and information about the past, current, and future market scenario, the Non-Small Cell Lung Carcinoma (NSCLC) market report will help and identify the concerns, for a smooth sail of small & medium as well as large enterprises.

Competitive Analysis

By Prominent Global Non-Small Cell Lung Carcinoma Industry Players

Key players in the market are non-small cell lung carcinoma market AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corp, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline plc, Novartis, Pfizer Inc, Roche Holding AG, Sun Pharmaceutical Industries Ltd.

With an extensive SWOT analysis, the FMI’s study presents the strengths, weaknesses, growth prospects, and challenges of each player. The report also includes important data including the sales strategy, pricing strategy, and marketing strategy adopted by these players in the Non-Small Cell Lung Carcinoma (NSCLC) market

Critical Questions Answered in the Report

What are ongoing trends that will shape the market growth curve for the global Non-Small Cell Lung Carcinoma (NSCLC) Industry?
What are the drivers and challenges affecting the Non-Small Cell Lung Carcinoma (NSCLC) Industry demand?
What are the recent technological advancements in the Non-Small Cell Lung Carcinoma (NSCLC) Industry?
What are key trends and opportunities that will prevail in the revenue growth of Non-Small Cell Lung Carcinoma (NSCLC) Industry players?
How will evolving regulatory policies impact market growth?
What is the impact of Covid-19 on the Non-Small Cell Lung Carcinoma (NSCLC) Industry?

Global Non-Small Cell Lung Carcinoma Industry: Segmentation

By Region

North America
Latin America
Europe
South Asia & Pacific
East Asia
Middle East & Africa

Detailed analysis of the geographical region and country-wise insights are offered in the latest Non-Small Cell Lung Carcinoma (NSCLC) Industry report with established market players as well as incumbents in the region.

Key Segments Profiled in the Global Non-Small Cell Lung Carcinoma Industry Survey

Type:

Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Large Cell Neuroendocrine Tumors

Treatment:

Chemotherapy
Targeted Therapy
- Bevacizumab (Avastin)
- Nectiumumbab (Portrazza)
- Ramucirumab (Cyramza)
Immunotherapy
- Nivolumab (Opdivo)
- Atezolizumab (Tecentrig)
Others

End User:

Hospitals
Homecare
Specialty Clinics
Others

Comprehensive analysis of the regional markets offers exclusive insights into the market performance across geographies along with relevant graphs, figures, and a list of tables.

Tap into Comprehensive Segmented Information – Purchase Now!
https://www.futuremarketinsights.com/checkout/16180

Why Future Market Insights?

Comprehensive analysis of evolving purchase patterns across different geographies
Detailed insights of market segments and sub-segments for historical as well as forecast period
A competitive analysis of prominent players and emerging players in the Non-Small Cell Lung Carcinoma (NSCLC) Industry
Detailed information about the product innovation, mergers, and acquisitions lined up in upcoming years
Groundbreaking research and market player-centric solutions for the upcoming decade according to the present market scenario

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Nandini Singh Sawlani

Global Alpha-1 Antitrypsin Deficiency Market for Spectacular Growth, Projected to Reach US$ 10 Billion by 2033 at a 12.8% CAGR

The global Alpha-1 Antitrypsin Deficiency (AATD) treatments market is anticipated to reach US$ 10 billion by 2033, growing at a compound annual growth rate of 12.8% from its projected US$ 3 billion market value in 2023. The increasing prevalence of respiratory ailments is one of the main factors propelling market expansion. In addition, the growing use of augmentation therapy is driving market growth.

The purpose of augmentation therapy is to increase the concentration of AAT in the respiratory tracts of patients by isolating the protein from healthy donors’ blood plasma. This treatment reduces the number of exacerbations, speeds up recovery, and decreases the emphysema’s growth. These components contribute to its increasing popularity among medical experts and patients.

It is also expected that research and development (R&D) investments will have a big impact on the sector. Many firms are working to create a portfolio that could alter the course of business by using their own competencies and expanding those through strategic alliances, R&D, and possible licensing, merger, and acquisition operations.

Preview Next-Level Insights Sample :
https://www.futuremarketinsights.com/reports/sample/rep-gb-16288

Key Takeaways from the Market Study

The global alpha-1 antitrypsin insufficiency market is expected to develop at a 12.8% CAGR by 2033, according to FMI.
The global market for Alpha-1 Antitrypsin Deficiency is anticipated to be over US$ 3 billion.
The global market for Alpha-1 Antitrypsin Deficiency is expected to be around US$ 10 billion.
According to Future Market Insights, Asia Pacific will grow at a CAGR of 12% between 2023 and 2033.
North America is expected to grow at a 12.7% CAGR between 2023 and 2033.
Europe is expected to grow at a 12.3% CAGR between 2023 and 2033.

“Within North America, the United States has dominated the market. The rising number of government funding, developments in gene therapy research and development, and the rising penetration of target illnesses are the primary drivers driving the Alpha-1 Antitrypsin Deficiency market expansion,” says an analyst at FMI

Market Competition

To address the present patient pool’s requests and counter the therapeutic market’s unmet needs, drug developers are increasingly moving their focus to alpha-1 antitrypsin deficiency (AATD).

Many novel medicines are being developed by several businesses, including ARO-AAT (Arrowhead Pharmaceutical), Alvelestat (Mereo Biopharma), and Inhaled AAT (Kamada).

ARO-AAT (Arrowhead Pharmaceutical) is a second-generation subcutaneously given drug that lowers hepatic synthesis of the mutant AAT protein by knocking down the alpha-1 antitrypsin (AAT) gene transcript. The business is now undertaking Phase II clinical studies to assess the drug’s safety, tolerability, and pharmacodynamic impact in AATD patients.

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16288

Key players in the Alpha-1 Antitrypsin Deficiency (A1ATD) market are:

Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
BoehringerIngelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
LFB Biomedicaments

Recent Developments:

Kamada Ltd., a vertically integrated global biopharmaceutical company focused on specialty plasma-derived therapeutics, announced in October 2022 that it had been awarded a three-year extension of an existing tender from the Canadian Blood Services (CBS) for the supply of four IgG products, CYTOGAM®, HEPAGAM®, VARIZIG®, and WINRHO® SDF, for a total estimated value of US$ 22 million. This award ensures that such products will continue to be sold in Canada. In November 2021, Kamada purchased four commercial pharmaceuticals that have been licensed by Health Canada and the United States Food and Drug Administration (FDA).

Key Segments Profiled in the Alpha-1 Antitrypsin Deficiency Market Industry Survey

By Product Type:

Augmentation Therapy
Bronchodilators
Corticosteroids
Oxygen Therapy

By Application:

Hospitals
Specialty Clinics
Pharmacies

Extensive Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16288

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Intratumoral Cancer Therapies Industry Set to Explode: Poised to Reach US$552 Billion by 2033 at 10% CAGR | FMI Analysis

The Global Intratumoral Cancer Therapies Industry is poised for a remarkable transformation, with a projected market value of US$552.36 billion by 2033 according to a recent report by Future Market Insights (FMI). This translates to a phenomenal Compound Annual Growth Rate (CAGR) of 10% expected throughout the 2023-2033 forecast period. This significant growth represents a substantial leap from the 2023 market value of US$212.96 billion.

Favorable Regulatory Landscape Paves the Way for Growth

The exceptional growth trajectory of the intratumoral cancer therapies market can be attributed primarily to a supportive regulatory environment for innovative cancer treatments. This follows a period of steady growth, with the market expanding at a CAGR of 7% from 2017 to 2022. The upcoming decade is expected to witness a significant acceleration in market growth fueled by these factors.

Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-16153

In terms of market share and revenue, the North American market is predicted to be the most lucrative market during the forecast period with a revenue share of 40%. The region’s growth is driven by the presence of various biotechnology and medical device firms. For instance, in March 2020, Johnson and Johnson received the US FDA Breakthrough Therapy Designation for JNJ-61186372 (JNJ-6372) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).

Key Takeaways from the Global Intratumoral Cancer Therapies Industry Study

From 2017-2022, the Intratumoral Cancer Therapies market grew at a CAGR of 7%.
The global Intratumoral Cancer Therapies market is expected to grow with a 10% CAGR during 2023-2033.
As of 2033, the Intratumoral Cancer Therapies market is expected to reach US$ 552.36 Billion.
The checkpoint inhibitors segment is poised to register the highest growth rate through 2033.
North America is expected to possess a 40% market share for the Intratumoral Cancer Therapies market in North America.
The European market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
By application, lung cancer is estimated to account for the largest share of the market.

“Cancer is among the top causes of mortality worldwide, and its incidence is increasing at an alarming rate. As a result, healthcare experts are concentrating on the development of efficient treatment and diagnosis solutions to reduce the incidence level.” says an FMI analyst

Reach Out to Our Analyst For Your Queries https://www.futuremarketinsights.com/ask-question/rep-gb-16153

Global Intratumoral Cancer Therapies Industry Competition

Key players in the Intratumoral Cancer Therapies market are Amgen Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Johnson & Johnson, and Eli Lily Company, F.

Gland Pharma has launched the cancer treatment medicine Bortezomib for Injection in the United States in 2022. The drug business stated in a statement that it has released the medicine in the US market through a partner who has acquired permission from the US Food and Drug Administration (USFDA). The business claims that its medicine is medically similar to Velcade for Injection from Takeda Pharmaceuticals. Bortezomib Intravenous is used to treat cancers such as myeloma and mantle cell lymphoma.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Intratumoral Cancer Therapies market, presenting a historical analysis from 2017 to 2022 and forecast statistics for the period of 2023-2033.

The study reveals essential insights based on technology (Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immune System Modulators, Adoptive Cell Transfer, Cytokines), application (Lung Cancer, Breast Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Others), end-users (Hospitals, Cancer Research Centres, Clinics) & region.

Grab Your Report on Discount Before It’s Gone!
https://www.futuremarketinsights.com/request-discount/rep-gb-16153

Key Segments Profiled in the Global Intratumoral Cancer Therapies Industry Survey

Technology:

Monoclonal Antibodies
Vaccines
Checkpoint Inhibitors
Cell Therapies
Immune System Modulators
Adoptive Cell Transfer
Cytokines

Application:

Lung Cancer
Breast Cancer
Melanoma
Prostate Cancer
Head & Neck Cancer
Others

End-users:

Hospitals
Cancer Research Centres
Clinics

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Nandini Singh Sawlani

Global Vessel Sealing Devices Industry Set for Explosive Growth, Reaching US$3.9 Billion by 2033 at 9% CAGR | FMI Analysis

The Global Vessel Sealing Devices Industry is on track for a remarkable surge, with a projected valuation of US$3.9 billion by 2033. This signifies a significant increase from its estimated value of US$1.65 billion in 2023. The market is poised for a new era of expansion, fueled by a robust Compound Annual Growth Rate (CAGR) of 9% anticipated throughout the forecast period.

Vascular-sealing instruments have become essential instruments in many medical fields; they are effective in laparoscopic, neck, and axillary dissection procedures, among other procedures. The vessel-sealing market has become a dominant force in the healthcare industry thanks to their adaptability and reliable performance, which have propelled them to the forefront of medical technology.

As these cutting-edge devices continue to outperform traditional methods in clinical applications, their influence is expected to steadily rise, shaping the future of surgical interventions. The vessel-sealing market’s upward trajectory is further fueled by the continuous evolution of surgical devices and a notable uptick in FDA approvals for vessel-sealing technologies. These regulatory milestones, combined with technological advancements, are anticipated to propel market expansion throughout the forecast period.

Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-16109

With fewer blood loss complications and less operating time, surgeons have improved safety and efficiency. Technological advancements in surgical devices and FDA guidelines regarding vessel-sealing devices are likely to drive the growth of the market.

Surgical procedures, product developments, and minimally invasive surgery are a few of the main drivers of this market.

Key Takeaways from the Global Vessel Sealing Devices Industry:

The vessel-sealing devices market is expected to increase at a notable CAGR of 9%
North America is a prominent market for vessel-sealing devices and is estimated to expand at a CAGR of 4.5% in the forecast period.
The United States is projected to account for 75% of the North American vessel-sealing devices market.
Hospitals and specialty clinics are expected to account for a prominent share of the market and rise at a CAGR of 4.86%.

Global Vessel Sealing Devices Industry Competitive Landscape

Manufacturers of vessel-sealing devices implement a variety of strategies to meet the needs of domestic and international customers as part of their competitive strategy. To satisfy the needs of domestic and international customers, companies such as Medtronic PLC maintain a steady emphasis on research and development to minimize risk during operations. Furthermore, to gain an advantage over their competition, key players continue to develop products through acquisition, partnerships, and innovation.

Key companies in the Global Vessel Sealing Devices Industry include

Medtronic PLC,
B Braun Melsungen AG, and
Erbe Medical India Pvt. Ltd,
Olympus Corporation,
Ethicon US LLC (Johnson & Johnson),
Boston Scientific Corporation,
BOWA-electronic GmbH & Co. KG,
OmniGuide Holdings Inc.,
CONMED Corporation, Bolder Surgical Holdings Inc,

Recent Developments in the Global Vessel Sealing Devices Industry

Olympus Corporation, a Japan-based manufacturer, offers Thunderbeat instrument lineups for endoscopic and open surgery. The device uses ultrasonic energy for fast and precise dissection.
In September 2022, Olympus expanded its global footprint with an investment of US$ 34 million in Coimbra, Portugal.
Ethicon’s Enseal X1 Curved Jaw Tissue Sealer was released in June 2021. This product is used for gynecological, thoracic, bariatric, and colorectal procedures.
Hologic Inc., a medical technology company, acquired Bolder Surgical, a developer and manufacturer of energy vessel sealing surgical devices, in October 2021 for US$ 160 million, to broaden their surgical portfolio.

Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/16109

Segments Covered in the Global Vessel Sealing Devices Industry Analysis

By Application

General Surgery
Laparoscopic Surgery

By End User

Hospitals & Specialty Clinics
Ambulatory Surgical Centers

By Region

North America
Latin America
Europe
The Middle East and Africa
East Asia

Author

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Contact Us:

Nandini Singh Sawlani

Global Chronic Wound Care Market Continues Upward Trajectory, Projected to Reach US$ 25,042.5 Million at a 3.8% CAGR

The global chronic wound care market is anticipated to grow at a CAGR of 3.8%. It is anticipated that by 2033, the market value will have grown from US$ 17,272.4 million in 2023 to US$ 25,042.5 million. The market for chronic wound care was estimated to be worth US$ 16,689.3 million in 2022, and in 2023, it is projected to increase at a rate of 3.5% year over year.

As a result of increased research and development by numerous governmental and non-governmental entities, new, creative items should hit the market. According to a Frontiers in Physics research, new smart bandages have been developed that allow clinicians to speak with patients without having to touch the wound.

In addition, scientists from the Indian Institute of Science have created magnetic nanofiber bandages that provide a non-invasive method of treating skin cancer. Researchers at IISc have created a bandage that is created by electrospinning a unique blend of nanoparticles. It has been demonstrated that for the best possible wound care, real-time monitoring of wound parameters at the wound site using a range of sensing modalities—including chemical and physical sensors—is crucial. A substantial amount of work has been put into developing technologies in recent years to track several parameters that affect the healing process of wounds, including pH, temperature, pressure, and infection status. To aid in wound diagnosis and treatment, advanced wound therapies have been created, such as local and on-demand drug administration.

Get a Sample Copy of the Report :
https://www.futuremarketinsights.com/reports/sample/rep-gb-16277

The advancement of technology and innovative 3D techniques, along with trackers and apps, will allow consumers to monitor the healing process of their finger wounds. For instance, Heriot-Watt University researchers developed tiny sensors that track wound healing and speed using a bandage under a bandage. There have been many studies on wound biology, but little is known about the physicality’s that contribute to wound healing, especially at the microscale, where advancement occurs at sub-hair widths. Crichton writes that few studies have actually been conducted on wounds.

Key Takeaways from the Market Study 

The global market size for chronic wound care is estimated to reach US$ 15.98 Billion by 2023.
According to the forecast, the market is expected to grow by 7% between 2023 and 2033, reaching a total of US$ 31.46 billion by 2033.
Across all wound dressing categories in 2023, advanced wound dressings accounted for 54% of the total market value.
Chronic wound care in North America expanded with a market share of 33% in 2022.
According to forecasts, by 2023 the diabetic ulcer market will account for 38% of the total market value.

“As diabetic ulcers become more prevalent and new drugs and devices are approved, artificial intelligence and technology are expected to play a significant role in growing sensor-based bandages.” comments a Future Market Insights analyst.

Competitive Landscape 

Research and the development of innovative diagnostic techniques are expected to be the focus of many companies in the near future, resulting in the expansion of their product lines, the acquisition of other companies, and the merger of their businesses.

Healthium Medtech, based in Bengaluru, has introduced its new wound dressing portfolio Theruptor Novo to manage chronic wound care such as diabetic foot ulcers and leg ulcers. Healthium expands its portfolio of advanced wound dressing products with Theruptor Novo. Approximately 25% of diabetics will develop a foot ulcer during their lifetime. As a result of complications caused by untreated diabetic foot ulcers, almost 1 lakh amputations have been registered in India today. In addition to being painful and expensive, foot ulcers require a lot of treatment.
In an era when complex chronic wound care are on the rise, while access to wound care nurse specialists is becoming more challenging, HARTMAN USA and Corstrata announce their partnership to support home health and other in-home providers. Clinical expertise and evidence-based treatment protocols are essential to integrate advanced wound dressings with a successful wound care program. BerryDunn’s National Healthcare at Home Best Practices and Future Insights Study, published in recent months by top-50 accounting firm BerryDunn, indicates that wound-certified specialists are on staff at all of the top 10% of home health agencies with positive financial surpluses.

Key Companies Profiled:

Paracrine, Inc.
Oneness Biotech
Biotissue
Polarity TE
MediWound
Anterogen Co., Ltd.
TR Therapeutics
RHEACELL GmbH & Co.KG
Smith & Nephew
Kaken Pharmaceutical

Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-16277

Key Segments Profiled in the Chronic Wound Care Market Industry Survey

Type:

Diabetic Ulcers
Pressure Ulcers
Venous Ulcers
Other Chronic Wounds

Product:

Advanced Wound Dressings
Wound Care Therapy
Active Therapy
Others

End User:

Hospital and Wound Care Centers
Homecare Settings
Others

Explore Full Market Analysis Now: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/16277

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube